We have recently analyzed longitudinal PB samples from patients with NSCLC undergoing anti–PD-1 therapy, and found that the percent change of the CX3CR1+ subset in PB CD8+ T cells from baseline (CX3CR1 score) associated with response and prognosis (16). Here, CD8A is linked to non-small cell lung carcinoma.